Results of a prospective phase II randomized study of deferasirox (Exjade) to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia (HREC/10/QRBW/135)

G.A. Kennedy, Royal Brisbane and Women's Hospital, Brisbane, Australia

Blood. 2012;120((21):): Abstract No. 3577.
Study details